CONy 2021 | The relevance of genetics in developing Alzheimer’s disease treatments

Richard Pither, PhD, Cytox Ltd, Oxford, UK, discusses the relevance of genetics in the development of effective treatment options for Alzheimer’s disease. The drug targets currently under investigation in various stages of clinical trial development have some level of genetic evidence either through human or animal model studies. Additionally, in the future, genetics might have a more vital role in drug development, particularly as pathways-specific targets are established where not every individual with Alzheimer’s disease will respond equally to a drug intervention. Therefore, it will be important to profile an Alzheimer’s disease patient and then match to an appropriate treatment, and according to Dr Pither, genetics will be critical in the process. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).